Results 81 to 90 of about 28,211 (255)
Advanced Therapeutics, Volume 9, Issue 1, January 2026.This study characterizes a camelid antibody (B10) with potent neutralizing activity against SARS‐CoV‐2 Wildtype and Omicron variants. Through binding assays, epitope mapping, pseudovirus neutralization, and AI‐driven modeling, the antibody is shown to target conserved RBD regions in a closed Spike conformation.
Katja Hanack +13 more
wiley +1 more source
Journal of Venomous Animals and Toxins including Tropical Diseases, 2014 Hump-nosed viper bites are frequent in southern India and Sri Lanka. However, the published literature on this snakebite is limited and its venom composition is not well characterized.
Milinda Withana +3 more
doaj +1 more source
A Rare Case of Thrombotic Thrombocytopenic Purpura Caused by Acute Pancreatitis [PDF]
, 2021 Emin Gemcioğlu +4 more
openalex +1 more source
Clinical Case Reports, Volume 14, Issue 1, January 2026.Timeline of events ABSTRACT Moderate‐to‐severe ulcerative colitis can be effectively treated with JAK‐1 inhibition, but platelet counts should be closely monitored, especially in active disease. We confirmed immune‐mediated thrombocytopenia (ITP) in one of our patients after the initiation of filgotinib. Whether this was drug‐induced is uncertain.
M. J. van der Hoff +2 more
wiley +1 more source
Eculizumab for Gemcitabine-Induced Hemolytic Uremic Syndrome: A Novel Therapy for an Emerging Condition [PDF]
, 2015 Introduction Atypical hemolytic uremic syndrome (aHUS), a thrombotic microangiopathy (TMA), is a disease characterized by hemolytic anemia, thrombocytopenia, and renal impairment. Gemcitabine, a commonly used chemotherapy, is emerging as a cause of aHUS.
Karkowsky, MD, Raphael +1 more
core +2 more sources
Infection and Drug Resistance, 2023 Fei Lv,1,2 Yue Zhao,2 Xing-Di Yang,2 Han-Zhu Chen,2 Wen-Ya Ren,2 Ling-Xia Chen,2 Qiao-Qiao Yi,2 Wei Zheng,2 Hong-Ying Pan2 1The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, People’s Republic of China ...
Lv F +8 more
doaj
Five years of caplacizumab – lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpura [PDF]
, 2023 Linus Alexander Völker +3 more
openalex +1 more source
A Diagnostic Challenge: Post‐Transfusion Purpura Unmasked After Multiple Transfusions
Clinical Case Reports, Volume 14, Issue 1, January 2026.ABSTRACT Post‐transfusion purpura (PTP) is a rare immune‐mediated post‐transfusion reaction resulting in severe thrombocytopenia. This case presents a 52‐year‐old female with profound thrombocytopenia following multiple transfusions. PTP was not initially suspected due to her history of comorbid anti‐phospholipid antibody syndrome (APS), chemotherapy ...
Jacintha Thomas +2 more
wiley +1 more source
MedwaveIntroduction Since the first description of Thrombotic Thrombocytopenic Purpura, caused by a severe deficiency of ADAMTS13, plasma exchange and immunosuppression have become standard treatments, allowing to decrease its high mortality rate.
Daniel Cathalifaud +6 more
doaj +1 more source
Acta Medica, 2004 Although much has been learned about the pathophysiologic process of thrombotic thrombocytopenic purpura (TTP), both diagnostically and therapeutically, since its initial description by Moschowitz in 1924, its etiology and treatments remain, in many ...
Leo McCarthy +5 more
doaj +1 more source